Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous Turoctocog Alfa Pegol in Hemophilia A
NCT02994407Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of turoctocog alfa pegol in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of adverse events. Started Jan 2017; status: completed.
02
Drugs
turoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02994407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994407.